Galecto Inc
GLTO25.260USD
+2.630+11.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
33.53MMarket Cap
LossP/E TTM
More Details of Galecto Inc Company
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Galecto Inc Info
Ticker SymbolGLTO
Company nameGalecto Inc
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Number of employees5
Security typeOrdinary Share
Fiscal year-endOct 29
Address75 State Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02109
Phone14570705210
Websitehttps://galecto.com/
Ticker SymbolGLTO
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Company Executives of Galecto Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
--
-192.00%
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Other
31.04%
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Other
31.04%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.16%
Hedge Fund
28.17%
Investment Advisor
17.71%
Corporation
15.10%
Venture Capital
1.85%
Research Firm
1.24%
Investment Advisor/Hedge Fund
0.67%
Other
3.10%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
45
791.78K
49.64%
+565.88K
2025Q3
44
164.38K
12.40%
-149.96K
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ikarian Capital LLC
285.71K
17.91%
+285.71K
--
Nov 30, 2025
Fidelity Management & Research Company LLC
238.88K
14.98%
+238.88K
--
Nov 28, 2025
Point72 Asset Management, L.P.
100.00K
6.27%
+100.00K
--
Nov 12, 2025
Goldfischer (Carl S)
41.96K
2.63%
-1.00
-0.00%
Dec 01, 2025
Danmarks Eksport- og Investeringsfond
29.52K
1.85%
-29.52K
-50.00%
Sep 30, 2024
Connective Capital Management, LLC
26.96K
1.69%
+26.96K
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Date
Ex-dividend Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
